More News

Awards and Grants
Postdoc Suying Bao Named Precision Medicine Fellow
Congratulations to Suying Bao, postdoctoral research scientist in the Chaolin Zhang lab, for recently being named an inaugural Precision Medicine Research fellow by Columbia’s Irving Institute of Clinical and Translational Research. The two-year fellowship aims to train postdocs to use genomics and complex clinical data to improve personalized and tailored clinical care and clinical outcomes.
Awards and Grants
Hyundai Awards Columbia $2.5M Grant for Pediatric Cancer Research
A team of researchers at Columbia University Irving Medical Center has recently been awarded a five-year $2.5 million grant from Hyundai Hope on Wheels to fund innovative pediatric cancer research, focusing on childhood cancers with poor prognosis. At Columbia, the team will target osteosarcoma, the most commonly diagnosed bone tumor in children and adolescents.
Awards and Grants
Michael Shen Wins Cancer Research Innovation Award
The Bladder Cancer Advocacy Network has awarded Professor Michael Shen, PhD, the 2018 Bladder Cancer Research Innovation Award. The honor singles out scientists whose creative, novel research has great potential to advance therapies for bladder cancer, the fifth most common cancer in the U.S.
Research News
New Insights on How the Reprogramming Factor LIN28 Regulates its Targets
A new study, led by Systems Biology Assistant Professor Chaolin Zhang, sheds light on a critical RNA-binding protein that is widely researched for its role in stem cell biology and its ties to cancer progression in multiple tissues. Published as the cover story in the journal, Molecular Cell, the study reveals how the LIN28 protein suppresses a specific family of microRNAs, called Let-7, which are selectively lost in cancer.
Research News
Matching Cancer Patients to Personalized Therapies
A novel N of 1 clinical trial at Columbia University is focusing on rare, untreatable malignancies that have progressed on multiple lines of therapy, with the goal of identifying and providing more effective, customized therapies for patients. The approach is grounded in a computational platform that enables accurate identification of proteins that represent critical tumor vulnerabilities and of the drug or drug combination that can most effectively disarm them.